Nermine S. Ghoniem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nermine S. Ghoniem has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Amr Mohamed Mahmoud
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo 11562, Egypt
4 shared publications Hala E. Zaazaa
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Kasr El Aini, Cairo University, Cairo, Egypt
3 shared publicationsManal Mohamed Fouad
Analytical Chemistry Department, Faculty of Pharmacy (Girls), Al-Azhar University, Nasr City, Cairo, Egypt
3 shared publicationsHany H. Monir
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Cairo, Egypt University, Kasr El-Aini Street, Cairo ET-11562, Egypt
2 shared publicationsHend M. Nagieb
Pharmaceutical Chemistry, Faculty of Pharmacy, Nahda University [NUB], Beni-Suef, Egypt
2 shared publicationsMaha M. Abdelrahman
Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Beni-suef University, Beni-suef, Egypt
2 shared publications
Latest Publications
- 28 August 2025
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 17 (34) , 6773-6781
CuO nanoparticle-enhanced electrochemical sensing of bromfenac in rabbit aqueous humor: a green analytical approach
Electrochemical techniques, particularly voltammetry, have emerged as powerful tools for the quantitative analysis of various analytes in different matrices.
- 28 August 2025
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 17 (34) , 6773-6781
CuO nanoparticle-enhanced electrochemical sensing of bromfenac in rabbit aqueous humor: a green analytical approach
Electrochemical techniques, particularly voltammetry, have emerged as powerful tools for the quantitative analysis of various analytes in different matrices.
- 1 April 2025
- Published by The Electrochemical Society in Journal of the Electrochemical Society
- Vol. 172 (4) , 047504
Nanoparticles Modified Solid-Contact Potentiometric Sensor for Selective Nanomolar Citicoline Determination
In light of the increasing concerns surrounding the hyper-inflammatory condition of COVID-19 on the neurovascular system, it’s crucial to explore treatments for both short- and long-term neurological issues. Citicoline sodium, known for its anti-inflammatory, antiviral, neuroprotective, and neurorestorative properties, plays a significant role in addressing neurological diseases, particularly cognitive defects following COVID-19. This work describes three glassy carbon potentiometric sensors fabricated to determine Citicoline sodium in its market dosage forms and spiked human plasma. The suggested PVC polymeric membrane/glassy carbon sensors were evaluated both before and after the incorporation of cobalt oxide and copper nanoparticles into the PVC polymeric membrane as an ion-to-electron transducer. This is the first solid-state sensor to quantitatively measure Citicoline sodium in biological fluids. The sensor’s performance was evaluated according to IUPAC recommendations, showing a quantification range of 1.00 × 10−8 to 1.00 × 10−2 M with low detection limits of (3.16 × 10−9 M and 1.78 × 10−9 M) for cobalt oxide and copper nanoparticle modified electrodes, respectively. Nanoparticle modification created a hydrophobic layer, improving electrode stability. The recommended potentiometric approach was evaluated for environmental friendliness and sustainability using GAPI, AGREE, and RGB-12 algorithm as greenness and whiteness assessment tools.
- 1 April 2025
- Published by The Electrochemical Society in Journal of the Electrochemical Society
- Vol. 172 (4) , 047504
Nanoparticles Modified Solid-Contact Potentiometric Sensor for Selective Nanomolar Citicoline Determination
In light of the increasing concerns surrounding the hyper-inflammatory condition of COVID-19 on the neurovascular system, it’s crucial to explore treatments for both short- and long-term neurological issues. Citicoline sodium, known for its anti-inflammatory, antiviral, neuroprotective, and neurorestorative properties, plays a significant role in addressing neurological diseases, particularly cognitive defects following COVID-19. This work describes three glassy carbon potentiometric sensors fabricated to determine Citicoline sodium in its market dosage forms and spiked human plasma. The suggested PVC polymeric membrane/glassy carbon sensors were evaluated both before and after the incorporation of cobalt oxide and copper nanoparticles into the PVC polymeric membrane as an ion-to-electron transducer. This is the first solid-state sensor to quantitatively measure Citicoline sodium in biological fluids. The sensor’s performance was evaluated according to IUPAC recommendations, showing a quantification range of 1.00 × 10−8 to 1.00 × 10−2 M with low detection limits of (3.16 × 10−9 M and 1.78 × 10−9 M) for cobalt oxide and copper nanoparticle modified electrodes, respectively. Nanoparticle modification created a hydrophobic layer, improving electrode stability. The recommended potentiometric approach was evaluated for environmental friendliness and sustainability using GAPI, AGREE, and RGB-12 algorithm as greenness and whiteness assessment tools.
- Open Access
- 31 October 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-11
A sustainable and green HPLC-PDA technique for the simultaneous estimation of Post-COVID-19 syndrome co-administered drugs with greenness and whiteness assessment
COVID-19 has been a growing global concern in the past four years. Several syndromes associated with this multi-organ viral infection have been observed since the outbreak. According to estimates, 10–15% of people with SARS-CoV- infection may have post-COVID-19 syndrome. Even months after infection, common residual signs and symptoms include myalgia, exhaustion, shortness of breath, rapid heartbeat, stroke, and memory and cognitive impairment which can negatively affect survivors’ quality of life and may consequently lead to their death. Therefore, it is necessary to think about potential therapy options for dealing with both short and long-term impacts. Paracetamol (a common analgesic and antipyretic) and Dexketoprofen Trometamol (a non-steroidal anti-inflammatory drug) are used together to relieve post-COVID symptoms like myalgia (muscle pain) and headache. Additionally, to prevent thrombotic events, Rivaroxaban is recommended for 35 days following discharge. Thus an eco-friendly HPLC-DAD technique was developed for simultaneous quantification of Paracetamol, Dexketoprofen Trometamol, and Rivaroxaban which are co-administered for treatment of post-COVID-19 syndrome. The suggested method was found to be linear in the concentration ranges of 3.00–45.00 µg/mL, 0.5–50.00 µg/mL, and 0.15–20.00 µg/mL, and a limit of detection down to 0.531 µg/mL, 0.095 µg/mL and 0.047 µg/mL for Paracetamol, Dexketoprofen Trometamol and Rivaroxaban, respectively. This method was effectively used to quantify the studied drugs in their bulk powder and spiked human plasma with high percentage recoveries (96.55–99.46%). The suggested approach was validated per International Conference on Harmonization (ICH) requirements and found to be within the acceptable ranges. The method was developed using Green Analytical Chemistry (GAC) principles, with the solvents used and run time having a significant effect on the method’s greenness. “Non-toxic” ethanol served as the organic modifier in the mobile phase, moreover, the total run time was 12 min making it suitable for the routine analysis of the mentioned drugs in plasma samples. To get a full image of the method’s greenness profile; two most recent greenness assessment tools, the Green Analytical Procedure Index (GAPI), and the Analytical GREEnness metric (AGREE), were employed, with White Analytical Chemistry (WAC) principles proving its environmental safety.
- 31 October 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-11
Open AccessA sustainable and green HPLC-PDA technique for the simultaneous estimation of Post-COVID-19 syndrome co-administered drugs with greenness and whiteness assessment
COVID-19 has been a growing global concern in the past four years. Several syndromes associated with this multi-organ viral infection have been observed since the outbreak. According to estimates, 10–15% of people with SARS-CoV- infection may have post-COVID-19 syndrome. Even months after infection, common residual signs and symptoms include myalgia, exhaustion, shortness of breath, rapid heartbeat, stroke, and memory and cognitive impairment which can negatively affect survivors’ quality of life and may consequently lead to their death. Therefore, it is necessary to think about potential therapy options for dealing with both short and long-term impacts. Paracetamol (a common analgesic and antipyretic) and Dexketoprofen Trometamol (a non-steroidal anti-inflammatory drug) are used together to relieve post-COVID symptoms like myalgia (muscle pain) and headache. Additionally, to prevent thrombotic events, Rivaroxaban is recommended for 35 days following discharge. Thus an eco-friendly HPLC-DAD technique was developed for simultaneous quantification of Paracetamol, Dexketoprofen Trometamol, and Rivaroxaban which are co-administered for treatment of post-COVID-19 syndrome. The suggested method was found to be linear in the concentration ranges of 3.00–45.00 µg/mL, 0.5–50.00 µg/mL, and 0.15–20.00 µg/mL, and a limit of detection down to 0.531 µg/mL, 0.095 µg/mL and 0.047 µg/mL for Paracetamol, Dexketoprofen Trometamol and Rivaroxaban, respectively. This method was effectively used to quantify the studied drugs in their bulk powder and spiked human plasma with high percentage recoveries (96.55–99.46%). The suggested approach was validated per International Conference on Harmonization (ICH) requirements and found to be within the acceptable ranges. The method was developed using Green Analytical Chemistry (GAC) principles, with the solvents used and run time having a significant effect on the method’s greenness. “Non-toxic” ethanol served as the organic modifier in the mobile phase, moreover, the total run time was 12 min making it suitable for the routine analysis of the mentioned drugs in plasma samples. To get a full image of the method’s greenness profile; two most recent greenness assessment tools, the Green Analytical Procedure Index (GAPI), and the Analytical GREEnness metric (AGREE), were employed, with White Analytical Chemistry (WAC) principles proving its environmental safety.
- Open Access
- 4 October 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-16
Pharmacokinetics of pulmonary indacaterol in rat lung using molecular imprinting solid-phase extraction coupled with RP-UPLC
Indacaterol, a β2 agonist prescribed for long-term management of patients with chronic obstructive pulmonary disease and asthma. In this study the first MISPE cartridges was developed using indacaterol as a template for its selective extraction from rat lung tissues, enabling precise pharmacokinetic evaluation at the drug’s site of action. A molecular imprinting polymer was synthesized using indacaterol as a template, methacrylic acid as a functional monomer and ethylene glycol dimethacrylate as a cross-linker with a molar ratio (1: 4: 20). The polymer was characterized by a high binding capacity of 9840 ± 0.86 and high selectivity with an imprinting factor of 4.53 ± 0.12. The synthesized polymer was utilized as a sorbent in solid-phase extraction to purify and extract indacaterol from lung tissue matrix. The optimum molecularly imprinted solid-phase extraction (MISPE) conditions were 20.0 mg of molecular imprinting polymer and non-imprinting polymer, acetonitrile as the loading solvent, acetonitrile: water (20: 80; by volume) as the washing solvent, and methanol: acetic acid (90: 10; by volume) as the eluting solvent. A pharmacokinetic study was performed for indacaterol in rat lungs using the synthesized and optimized MISPE cartridge as a tool for sample purification. These parameters were determined in the lung tissues of rats emphasizing the local exposure of indacaterol to its target organ. The Cmax and Tmax were 51.020 ± 2.810 µg mL− 1 and 0.083 ± 0.001 h, respectively. The AUC 0−24 and AUC0 − inf were 175.920 ± 1.053 and 542.000 ± 5.245 µg h mL− 1, respectively. The elimination rate constant was 0.014 ± 0.00012 h− 1 and the half-life time was 48.510 ± 0.012 h. This study successfully developed and optimized MISPE cartridges using indacaterol as a template, enabling precise pharmacokinetic evaluation in rat lung tissues. The cartridges demonstrated high binding capacity and selectivity, providing crucial insights into the local exposure of indacaterol at its site of action.
- 4 October 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-16
Open AccessPharmacokinetics of pulmonary indacaterol in rat lung using molecular imprinting solid-phase extraction coupled with RP-UPLC
Indacaterol, a β2 agonist prescribed for long-term management of patients with chronic obstructive pulmonary disease and asthma. In this study the first MISPE cartridges was developed using indacaterol as a template for its selective extraction from rat lung tissues, enabling precise pharmacokinetic evaluation at the drug’s site of action. A molecular imprinting polymer was synthesized using indacaterol as a template, methacrylic acid as a functional monomer and ethylene glycol dimethacrylate as a cross-linker with a molar ratio (1: 4: 20). The polymer was characterized by a high binding capacity of 9840 ± 0.86 and high selectivity with an imprinting factor of 4.53 ± 0.12. The synthesized polymer was utilized as a sorbent in solid-phase extraction to purify and extract indacaterol from lung tissue matrix. The optimum molecularly imprinted solid-phase extraction (MISPE) conditions were 20.0 mg of molecular imprinting polymer and non-imprinting polymer, acetonitrile as the loading solvent, acetonitrile: water (20: 80; by volume) as the washing solvent, and methanol: acetic acid (90: 10; by volume) as the eluting solvent. A pharmacokinetic study was performed for indacaterol in rat lungs using the synthesized and optimized MISPE cartridge as a tool for sample purification. These parameters were determined in the lung tissues of rats emphasizing the local exposure of indacaterol to its target organ. The Cmax and Tmax were 51.020 ± 2.810 µg mL− 1 and 0.083 ± 0.001 h, respectively. The AUC 0−24 and AUC0 − inf were 175.920 ± 1.053 and 542.000 ± 5.245 µg h mL− 1, respectively. The elimination rate constant was 0.014 ± 0.00012 h− 1 and the half-life time was 48.510 ± 0.012 h. This study successfully developed and optimized MISPE cartridges using indacaterol as a template, enabling precise pharmacokinetic evaluation in rat lung tissues. The cartridges demonstrated high binding capacity and selectivity, providing crucial insights into the local exposure of indacaterol at its site of action.
- Open Access
- 18 September 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-11
“Eco-friendly HPLC method for analysis of dipyrone and hyoscine in different matrices with biomonitoring”
A selective, precise, and accurate reversed HPLC method has been developed and validated for simultaneous separation and determination of two veterinary drugs, dipyrone and hyoscine, in their combined dosage form in the presence of their official impurities, namely 4-aminoantipyrine and tropic acid, in addition to the formulated preservative: phenol. The linearity range was found to be (1.00–35.00 µg/mL) for dipyrone and (2.50–50.00 µg/mL) for hyoscine. It exhibited a satisfactory linearity regression R (0.9999) for both drugs with LOD 0.22 µg/mL and 0.72 µg/mL and LOQ 0.65 µg/mL and 2.19 µg/mL for dipyrone and hyoscine, respectively. Additionally, the two cited drugs were also determined in the presence of dipyrone active metabolite 4-aminoantipyrine using diclofenac as an internal standard in bovine urine. The linearity range was found to be (15–75 µg/mL) for dipyrone, (2.5–60 µg/mL) for hyoscine, and (2.5–60 µg/mL) for 4-aminoantipyrine with linearity regression R (0.9999–0.9998). The LLOQ (15, 2.5, 2.5 µg/mL), LQC (45, 7.5, 7.5 µg/mL), MQC (55, 25, 25 µg/mL), and HQC (60, 50 50 µg/mL) were determined for dipyrone, hyoscine and 4-aminoantipyrine, respectively. UV detection was carried out at 220 nm. The method was validated according to the ICH guidelines, as well as according to FDA guidelines for determining both drugs in bioanalytical matrices and both proved accuracy and precision. A statistical comparison was made between the results obtained and those obtained by the reported method, showing no significant difference in accuracy and precision at p = 0.05. The suggested method was proved eco-friendly through a greenness assessment using two different tools (The analytical eco-scale scored 83, and the AGREE-Analytical Greenness Metric approach scored 0.83). The suggested method can be used in the routine work of quality control labs, screening for drug abuse, and ensuring clean sport for horse racing.
- 18 September 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-11
Open Access“Eco-friendly HPLC method for analysis of dipyrone and hyoscine in different matrices with biomonitoring”
A selective, precise, and accurate reversed HPLC method has been developed and validated for simultaneous separation and determination of two veterinary drugs, dipyrone and hyoscine, in their combined dosage form in the presence of their official impurities, namely 4-aminoantipyrine and tropic acid, in addition to the formulated preservative: phenol. The linearity range was found to be (1.00–35.00 µg/mL) for dipyrone and (2.50–50.00 µg/mL) for hyoscine. It exhibited a satisfactory linearity regression R (0.9999) for both drugs with LOD 0.22 µg/mL and 0.72 µg/mL and LOQ 0.65 µg/mL and 2.19 µg/mL for dipyrone and hyoscine, respectively. Additionally, the two cited drugs were also determined in the presence of dipyrone active metabolite 4-aminoantipyrine using diclofenac as an internal standard in bovine urine. The linearity range was found to be (15–75 µg/mL) for dipyrone, (2.5–60 µg/mL) for hyoscine, and (2.5–60 µg/mL) for 4-aminoantipyrine with linearity regression R (0.9999–0.9998). The LLOQ (15, 2.5, 2.5 µg/mL), LQC (45, 7.5, 7.5 µg/mL), MQC (55, 25, 25 µg/mL), and HQC (60, 50 50 µg/mL) were determined for dipyrone, hyoscine and 4-aminoantipyrine, respectively. UV detection was carried out at 220 nm. The method was validated according to the ICH guidelines, as well as according to FDA guidelines for determining both drugs in bioanalytical matrices and both proved accuracy and precision. A statistical comparison was made between the results obtained and those obtained by the reported method, showing no significant difference in accuracy and precision at p = 0.05. The suggested method was proved eco-friendly through a greenness assessment using two different tools (The analytical eco-scale scored 83, and the AGREE-Analytical Greenness Metric approach scored 0.83). The suggested method can be used in the routine work of quality control labs, screening for drug abuse, and ensuring clean sport for horse racing.
- Open Access
- 22 January 2024
- Published by Springer Nature in BMC Chemistry
- Vol. 18 (1) , 1-19
AQbD TLC-densitometric method approach along with green fingerprint and whiteness assessment for quantifying two combined antihypertensive agents and their impurities
Preserving the environment, reducing the amount of waste resulting from chemical trials, and reducing the amount of energy consumed have currently become a pivotal global trend. An analytical quality by design (AQbD) based eco-friendly TLC-densitometric method was implemented for quantifying two antihypertensive agents, captopril (CPL) and hydrochlorothiazide (HCZ), along with their impurities; captopril disulphide (CDS), chlorothiazide (CTZ) and salamide (SMD). The analytical target profile (ATP) was first identified, followed by selecting the critical analytical attributes (CAAs), such as retardation factors and resolution between the separated peaks. Critical method parameters (CMPs) that may have a crucial influence on CAAs were identified and emanated through the quality risk assessment phase. A literature survey-based preliminary studies were performed, followed by optimization of the selected CMPs through a custom experimental design to attain the highest resolution with optimum retardation factors. Moreover, method robustness was also tested by testing the design space. Complete separation of the drugs and their impurities was achieved using ethyl acetate: glacial acetic acid (6: 0.6, v/v) as a developing system applied to a 12 cm length TLC plate at room temperature with UV scanning at 215 nm. Calibration graphs were found to be linear in the ranges of (0.70–6.00), (0.10–2.00), (0.20–1.00), (0.07–1.50) and (0.05–1.00) µg/band corresponding to CPL, HCZ, CDS, CTZ, and SMD, respectively. Four different green metric tools were used to evaluate the greenness profile of the proposed method, and results showed that it is greener than the reported HPLC method. Method whiteness assessment was also conducted. Moreover, the method performance was evaluated following the ICH guidelines, and the outcomes fell within the acceptable limits. The developed method could be approved for routine assay of the cited components in their pharmaceutical formulations and bulk powder without interference from the reported impurities. The issue of concern is saving money, especially in developing countries.
- 22 January 2024
- Published by Springer Nature in BMC Chemistry
- Vol. 18 (1) , 1-19
Open AccessAQbD TLC-densitometric method approach along with green fingerprint and whiteness assessment for quantifying two combined antihypertensive agents and their impurities
Preserving the environment, reducing the amount of waste resulting from chemical trials, and reducing the amount of energy consumed have currently become a pivotal global trend. An analytical quality by design (AQbD) based eco-friendly TLC-densitometric method was implemented for quantifying two antihypertensive agents, captopril (CPL) and hydrochlorothiazide (HCZ), along with their impurities; captopril disulphide (CDS), chlorothiazide (CTZ) and salamide (SMD). The analytical target profile (ATP) was first identified, followed by selecting the critical analytical attributes (CAAs), such as retardation factors and resolution between the separated peaks. Critical method parameters (CMPs) that may have a crucial influence on CAAs were identified and emanated through the quality risk assessment phase. A literature survey-based preliminary studies were performed, followed by optimization of the selected CMPs through a custom experimental design to attain the highest resolution with optimum retardation factors. Moreover, method robustness was also tested by testing the design space. Complete separation of the drugs and their impurities was achieved using ethyl acetate: glacial acetic acid (6: 0.6, v/v) as a developing system applied to a 12 cm length TLC plate at room temperature with UV scanning at 215 nm. Calibration graphs were found to be linear in the ranges of (0.70–6.00), (0.10–2.00), (0.20–1.00), (0.07–1.50) and (0.05–1.00) µg/band corresponding to CPL, HCZ, CDS, CTZ, and SMD, respectively. Four different green metric tools were used to evaluate the greenness profile of the proposed method, and results showed that it is greener than the reported HPLC method. Method whiteness assessment was also conducted. Moreover, the method performance was evaluated following the ICH guidelines, and the outcomes fell within the acceptable limits. The developed method could be approved for routine assay of the cited components in their pharmaceutical formulations and bulk powder without interference from the reported impurities. The issue of concern is saving money, especially in developing countries.
- Open Access
- 7 November 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-14
Greenness assessment of UPLC/MS/MS method for determination of two antihypertensive agents and their harmful impurities with ADME/TOX profile study
Hypertension is described by the world health organization (WHO) as a serious medical problem that significantly affects the heart, brain and kidneys. It is a major cause of premature death worldwide. The present study aims to quantify the combination of captopril (CPL), hydrochlorothiazide (HCZ) and their harmful impurities; captopril disulphide (CDS), chlorothiaizde (CTZ) and salamide (SMD). In-silico study was conducted for estimation of pharmacokinetic parameters (ADMET) as well as toxicity profile of the proposed impurities. The results showed that the three impurities under investigation had poor permeability to CNS and cannot pass the blood–brain barrier (BBB), reducing the likelihood of causing side effects in the brain. On the other hand, all studied impurities were found to be hepatotoxic. In consequence, a highly sensitive and green ultra-performance liquid chromatography- tandem mass spectrometric (UPLC/MS/MS) method was developed and validated for separation of the cited drugs in the presence of their harmful impurities; methanol and 0.1% formic acid (90:10, v/v) mixture was used as a mobile phase, eluted at a constant flow rate of 0.7 mL/min at room temperature. Detection was adopted using a tandem mass spectrometer in a positive mode only for CPL and negative mode for HCZ, CDS, CTZ and SMD. Separation was performed within 1 min. Calibration graphs were found to be linear in the ranges of (50.0–500.0 ng mL−1), (20.0–500.0 ng mL−1), (10.0–250.0 ng mL−1), (5.0–250.0 ng mL−1) and (20.0–400.0 ng mL−1) corresponding to CPL, HCZ, CDS, CTZ and SMD, respectively. Additionally, comparative study of greenness profile was established for the proposed and reported methods using five green metric tools. The proposed method was found to be greener than the reported HPLC method. The developed (UPLC/MS/MS) method was validated according to (ICH) guidelines and it was found to has greater sensitivity, shorter analysis time and lower environmental impact compared to the reported methods.
- 7 November 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-14
Open AccessGreenness assessment of UPLC/MS/MS method for determination of two antihypertensive agents and their harmful impurities with ADME/TOX profile study
Hypertension is described by the world health organization (WHO) as a serious medical problem that significantly affects the heart, brain and kidneys. It is a major cause of premature death worldwide. The present study aims to quantify the combination of captopril (CPL), hydrochlorothiazide (HCZ) and their harmful impurities; captopril disulphide (CDS), chlorothiaizde (CTZ) and salamide (SMD). In-silico study was conducted for estimation of pharmacokinetic parameters (ADMET) as well as toxicity profile of the proposed impurities. The results showed that the three impurities under investigation had poor permeability to CNS and cannot pass the blood–brain barrier (BBB), reducing the likelihood of causing side effects in the brain. On the other hand, all studied impurities were found to be hepatotoxic. In consequence, a highly sensitive and green ultra-performance liquid chromatography- tandem mass spectrometric (UPLC/MS/MS) method was developed and validated for separation of the cited drugs in the presence of their harmful impurities; methanol and 0.1% formic acid (90:10, v/v) mixture was used as a mobile phase, eluted at a constant flow rate of 0.7 mL/min at room temperature. Detection was adopted using a tandem mass spectrometer in a positive mode only for CPL and negative mode for HCZ, CDS, CTZ and SMD. Separation was performed within 1 min. Calibration graphs were found to be linear in the ranges of (50.0–500.0 ng mL−1), (20.0–500.0 ng mL−1), (10.0–250.0 ng mL−1), (5.0–250.0 ng mL−1) and (20.0–400.0 ng mL−1) corresponding to CPL, HCZ, CDS, CTZ and SMD, respectively. Additionally, comparative study of greenness profile was established for the proposed and reported methods using five green metric tools. The proposed method was found to be greener than the reported HPLC method. The developed (UPLC/MS/MS) method was validated according to (ICH) guidelines and it was found to has greater sensitivity, shorter analysis time and lower environmental impact compared to the reported methods.
- 1 September 2022
- Published by The Electrochemical Society in Journal of the Electrochemical Society
- Vol. 169 (9) , 097504
Electrochemical Sensor for Meropenem Therapeutic Monitoring in Human Plasma Based on Carbon Nanotubes Modified Basal Pyrolytic Graphite Electrode
Sensitive, precise, and fast differential pulse voltammetric (DPV) method has been developed for determination of meropenem (MER) in pure form, pharmaceutical dosage form, and human plasma. The fabricated sensors are based on basal-plane pyrolytic graphite electrode (BPPGE) substrates that was modified by coating the surface with carbon nanotubes. The modified electrode showed detectable enhancement of the anodic peak current of meropenem from 25.8 to 35.7 μA. Effect of both pH and scan rate on peak current and potential were studied, optimum conditions were found to be at pH = 3.0 and scan rate of 100 mV.s−1. A linear response was obtained over the concentration range of 3.0 × 10−7 to 7.0 × 10−5 M MER in aqueous buffer solution. The suggested sensor is highly sensitive, has short response time, capable of MER detection as low concentration as 1.5 × 10−6 M in human plasma. The proposed sensors shows a great potential towards future fabrication of a point-of-care device to monitor MER level in patients’ plasma to ensure drug safety and efficacy for patients in intensive care unit.
- 1 September 2022
- Published by The Electrochemical Society in Journal of the Electrochemical Society
- Vol. 169 (9) , 097504
Electrochemical Sensor for Meropenem Therapeutic Monitoring in Human Plasma Based on Carbon Nanotubes Modified Basal Pyrolytic Graphite Electrode
Sensitive, precise, and fast differential pulse voltammetric (DPV) method has been developed for determination of meropenem (MER) in pure form, pharmaceutical dosage form, and human plasma. The fabricated sensors are based on basal-plane pyrolytic graphite electrode (BPPGE) substrates that was modified by coating the surface with carbon nanotubes. The modified electrode showed detectable enhancement of the anodic peak current of meropenem from 25.8 to 35.7 μA. Effect of both pH and scan rate on peak current and potential were studied, optimum conditions were found to be at pH = 3.0 and scan rate of 100 mV.s−1. A linear response was obtained over the concentration range of 3.0 × 10−7 to 7.0 × 10−5 M MER in aqueous buffer solution. The suggested sensor is highly sensitive, has short response time, capable of MER detection as low concentration as 1.5 × 10−6 M in human plasma. The proposed sensors shows a great potential towards future fabrication of a point-of-care device to monitor MER level in patients’ plasma to ensure drug safety and efficacy for patients in intensive care unit.